,i  #aafth ,,congress  #ast ,session    
,h4 ,r4 #bbji  ,,in ,,the ,,house ,,of  
,,representatives  ,april #aj1 #bjai    
,mr4 ,meadows introduced the following  
bill2 which was referred to the         
,committee on ,ways and ,means  ,a      
,,bill  ,to establish the position of   
,chief ,pharmaceutical ,negotiator in   
the ,office of the ,united ,states      
,trade ,representative responsible for  
conducting trade negotiations and       
enforcing trade agreements related to   
acts1 policies1 and practices of foreign
 governments that fail to appropriately 
reward ,united ,states innovation with  
respect to pharmaceuticals1 and for     
other purposes4  #a4 ,short title ,this 
,act may be cited as the ,fixing ,global
 ,freeloading ,act4  #b4 ,findings      
,congress finds the following3  7#a7    
,international government price controls
 of pharmaceutical products and services
 creates an unfair playing field because
 the rest of the world relies on and    
benefits from the biopharmaceutical     

innovation that takes place in the      
,united ,states1 which supports #d4e    
million jobs and amounts to #ij billion 
in research and development investment  
every year4  7#b7 ,the ,united ,states  
pays the cost of developing innovative  
and life-saving prescription drugs while
 other countries refuse to pay their    
fair share for their health care needs4 
7#c7 ,in fact1 some of the ,united      
,states trading partners are ignoring   
obligations established under trade     
agreements and setting up discriminatory
 rules to benefit local competitors over
 ,united ,states companies4  7#d7       
,between #bjaj and #bjaa1 #bc countries 
implemented #hi distinct measures to    
contain government spending on          
prescription drugs4 ,most used their    
single-payer healthcare systems to      
impose drug price controls alongside    
increased copayments1 value-added tax   
rates on prescription drugs1 and other  
measures4  7#e7 ,studies have shown that
 government price controls result in    

prices below actual market value and    
push the burden of paying for innovative
 treatments on to ,united ,states       
patients4  #c4 ,chief ,pharmaceutical   
,negotiator  7a7 ,in general ,section   
#ada of the ,trade ,act of #aigd 7#ai   
,u4,s4,c4 #baga7 is amended--  7#a7 in  
subsection 7b77#b7-- 7,a7 by striking   
and one ,chief ,innovation and          
,intellectual ,property ,negotiator and 
inserting one ,chief ,innovation and    
,intellectual ,property ,negotiator1 and
 one ,chief ,pharmaceutical ,negotiator2
  7,b7 by striking or the ,chief        
,innovation and ,intellectual ,property 
,negotiator and inserting the ,chief    
,innovation and ,intellectual ,property 
,negotiator1 or the ,chief              
,pharmaceutical ,negotiator2 and  7,c7  
by striking and the ,chief ,innovation  
and ,intellectual ,property ,negotiator 
and inserting the ,chief ,innovation and
 ,intellectual ,property ,negotiator1   
and the ,chief ,pharmaceutical          
,negotiator2 and  7#b7 in subsection    

7c71 by adding at the end the following 
new paragraph3  7#g7 ,the principal     
function of the ,chief ,pharmaceutical  
,negotiator shall be to conduct trade   
negotiations and to enforce trade       
agreements relating to ,united ,states  
pharmaceutical products and services4   
,the ,chief ,pharmaceutical ,negotiator 
shall be a vigorous advocate on behalf  
of ,united ,states pharmaceutical       
interests4 ,the ,chief ,pharmaceutical  
,negotiator shall perform such other    
functions as the ,united ,states ,trade 
,representative may direct4  4  7b7     
,compensation ,section #ecad of title   
#e1 ,united ,states ,code is amended by 
striking ,chief ,innovation and         
,intellectual ,property ,negotiator1    
,office of the ,united ,states ,trade   
,representative4 and inserting the      
following3  ,chief ,innovation and      
,intellectual ,property ,negotiator1    
,office of the ,united ,states ,trade   
,representative4  ,chief ,pharmaceutical
 ,negotiator1 ,office of the ,united    

,states ,trade ,representative4  4  7c7 
,report required ,not later than one    
year after the appointment of the first 
,chief ,pharmaceutical ,negotiator      
pursuant to paragraph 7#b7 of section   
#ada7;b7 of the ,trade ,act of #aigd1 as
 amended by subsection 7a71 and annually
 thereafter1 the ,united ,states ,trade 
,representative shall submit to the     
,committee on ,finance of the ,senate   
and the ,committee on ,ways and ,means  
of the ,house of ,representatives a     
report describing in detail--  7#a7     
enforcement actions taken by the ,trade 
,representative during the one-year     
period preceding the submission of the  
report to ensure the protection of      
,united ,states pharmaceutical products 
and services2 and  7#b7 other actions   
taken by the ,trade ,representative to  
advance ,united ,states pharmaceutical  
products and services4